A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...

DelveInsight's Hereditary Transthyretin Amyloidosis Market Insights report includes a comprehensive understanding of current ...

Acoramidis reduced the cumulative burden of cardiovascular outcomes at 30 months in patients with transthyretin amyloid ...

University College London's National Amyloidosis Center leads a multinational team reporting that a single infusion of an in ...

Cardiologist Dmitry Yaranov highlights amyloidosis as an underdiagnosed cause of heart failure, often mistaken for ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

PITTSBURGH (KDKA) -- Amyloidosis is a rare condition that used to almost always be fatal, but doctors are finally making progress in treating it. "I had so many symptoms, and I really didn't think ...

Amyloidosis is classified into three main forms depending on the cause of the condition. The condition is also referred to as either localized when only one site of the body is affected, or systemic ...

Monoclonal gammopathies represent a broad differential diagnosis and require a thorough evaluation for clinical significance. Smoldering multiple myeloma is a clinical entity that does not require ...

Interviewer: Amyloidosis is a rare and possibly debilitating disease, which affects about 4,000 people a year in the United States. If left untreated, the disease can cause severe organ damage, so ...

Q: Which doctor should I consult for amyloidosis? A: You may initially consult a physician who may refer you to other specialist doctors such as an oncologist (doctor who treats cancer) or a bone ...

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 abstract at the upcoming ...